Sat Nov 1 20:09:01 SGT 2014  
SINGAPORE
GENITAL™
    Genital warts treatment, Singapore (SG)
HIV STD TESTING SINGAPORE™
Within 3 days after unprotected sex, stop HIV infection with Post-Exposure Prophylaxis treatment 10 days after unprotected sex, detect HIV infection with the DNA test 28 days after unprotected sex, accurately detect HIV infection with the 20 minute rapid test
Full & comprehensive sexually transmitted disease testing
Males: do not urinate for at least 4 hours before arriving
Females: testing is more accurate when you are not menstruating

Genital warts treatment, Singapore (SG) | HIV STD TESTING SINGAPORE™

Summary

Genital warts treatment, Singapore (SG) | HIV STD TESTING SINGAPORE™ @singaporegenital_com: Genital warts (condyloma, condylomata acuminata, venereal wart, anal wart, anogenital wart, "cauliflower" sex disease) screening/diagnosis, testing/check treatment/removal/cure, Singapore. Private and confidential service. Definitions, references, and latest news.

Description

Genital warts: penile warts / vaginal warts / anal warts / anogenital warts / venereal warts / condyloma / condylomata acuminata / "cauliflower" sex disease.

References

Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
SHIM CLINIC
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Genital warts treatment, Singapore (SG)
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.

Sexual risk (of HIV/STD/pregnancy), and what you can do before and after exposure.

Timeline Event / Available resources
HIV STD Pregnancy
Before exposure
Abstain from sex, Be faithful, or Condom use
Circumcision (males only)
Contraception
(females only)
HIV PrEP (pre-exposure prophylaxis) STD vaccine:
- Hepatitis vaccine
- HPV vaccine
STD / HIV exposure
Unsafe sex / unprotected sex:
No condom / Condom broke / Condom slip
0-72 hours HIV prevention
HIV PEP (post-exposure prophylaxis) treatment
- Stop HIV infection after exposure.
STD testing
If STD symptoms appear, then do STD treatment.
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.
Emergency contraception
(females only)
2 weeks HIV DNA PCR test
1 month 20 minute SD Bioline HIV Ag/Ab Combo HIV rapid test:
- Fingerprick blood sampling.
3 months 20 minute OraQuick® HIV rapid test:
- Oral saliva or
- Fingerprick blood sampling.
Full & comprehensive STD testing
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.

References


Latest News

Long-term cumulative detection of human papillomavirus among HIV seropositive women
Fri, 31 Oct 2014 01:24:05 +0100 | AIDS

Frequency of Betapapillomavirus infections among HIV infected and uninfected Black Zimbabweans with cutaneous lesions
Thu, 30 Oct 2014 18:25:14 +0100 | Journal of Medical Virology
Human papillomavirus (HPV) types from the Betapapillomavirus (β‐HPV) genus are plentiful in non‐melanoma skin cancers and warts among Caucasians, but there is paucity of information among black Africans. To determine the frequency of β‐HPV genotypes in cutaneous infections among Black Zimbabweans, a cross‐sectional study was carried out in which blood samples and skin biopsies were collected from patients infected and uninfected with HIV attending a referral hospital. We included 144 participants (72 infected and 72 uninfected with HIV) with clinically apparent cutaneous warts (n = 34), suspected non‐melanoma skin cancers (n = 98) and Kaposi sarcoma (KS) (n = 18). The skin biopsies were analyzed for HPV DNA presence and type. β‐HPV DNA was identified among 70% (1...

A meditation on medications, among other things
Thu, 30 Oct 2014 00:00:00 +0100 | Neurology Neuroimmunology and Neuroinflammation
This third issue of Neurology® Neuroimmunology & Neuroinflammation incorporates a number of fascinating and informative clinical reports, including a presentation of prion disease as hyperacusis from Merkler et al.1 as well as a case of NMDA receptor antibody disease associated with bilateral sensorineural hearing loss from Taraschenko et al.2 In the case reported by Merkler et al., central auditory processing is the suspected pathophysiology, while the data from Taraschenko et al. suggest that the cochlear apparatus was directly targeted by pathogenic autoantibodies. Together the 2 cases illustrate how much neurophysiology can be gleaned from thoughtful study of these unusual patients. We also present a transient episode of autoimmune autonomic ganglionopathy (AAG) from Baker et a...

Bivalent HPV vaccine safety depending on subtypes of juvenile idiopathic arthritis
Thu, 30 Oct 2014 00:00:00 +0100 | Annals of the Rheumatic Diseases
We read with great interest the article by Heijstek et al1 regarding the safety of the bivalent human papillomavirus (HPV) vaccine in patients with juvenile idiopathic arthritis (JIA). Their prospective controlled observational cohort study of 68 patients revealed no differences in adverse events between female JIA patients and healthy girls. The authors concluded that the vaccine is well tolerated in JIA patients. Most reports regarding the safety of the HPV vaccine, including premarket cohort studies2–4 and postlicensing safety monitoring surveys,5 suggest no apparent causal relationship between the vaccine and serious adverse events (SAEs) in young girls. Now the focus has moved to vaccine safety in patients with illnesses such as immunological disorders.6 Heijstek et al1 did repo...

Response to: 'Bivalent HPV vaccine safety depending on subtypes of juvenile idiopathic arthritis' by Dr Akioka
Thu, 30 Oct 2014 00:00:00 +0100 | Annals of the Rheumatic Diseases
We thank Dr Akioka for the comments1 on our recent study on the bivalent human papillomavirus (HPV) vaccine in patients with juvenile idiopathic arthritis (JIA).2 Akioka and coworkers describe a patient with enthesitis-related JIA after receiving the bivalent HPV vaccine. It was unclear whether this patient newly developed JIA or experienced a flare of pre-existing JIA. With regard to the former, vaccinations are indeed often described as potential environmental triggers inducing autoimmune diseases in genetically susceptible individuals.3 4 For example, cases of systemic lupus erythematosus have been described after the quadrivalent HPV vaccine.5 However, in a large register-based cohort study, including 997 585 girls among whom 296 826 received a total of 696 420 quadrival...

Could sex with 21 women 'cut prostate risk'?
Wed, 29 Oct 2014 10:30:00 +0100 | NHS News Feed
ConclusionThis case-control study has suggested that having several female partners over a man’s lifetime is associated with a protective effect against prostate cancer, whereas having several male partners increased the risk.However, case-control studies like this one cannot prove that having several female partners reduces the risk of prostate cancer, or that having more male partners increases risk. When it comes to complex issues such as lifestyle, sexuality and cancer outcomes, there could be a wide range of contributing factors.If having multiple female partners reduced prostate cancer risk, it would be expected that the more partners you had the lower your risk would be. However, this study did not find such a relationship between number of female partners and associated risk. The...

Interaction of quantitative 18F‐FDG‐PET‐CT imaging parameters and human papillomavirus status in oropharyngeal squamous cell carcinoma
Wed, 29 Oct 2014 00:00:00 +0100 | Head and Neck
Conclusions. 18F‐FDG‐PET‐CT parameters are lower in HPV‐positive than in HPV‐negative patients. Low pretreatment SUV‐values in HPV‐positive OPSCC may be at least partly explained by HPV‐induced tumor changes. Head Neck, 2014 (Source: Head and Neck)

Randomized phase III study of 2 cisplatin‐based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: Impact of changing disease epidemiology on contemporary trial design
Wed, 29 Oct 2014 00:00:00 +0100 | Head and Neck
ConclusionMultiagent was not superior to single‐agent chemoradiotherapy. Overrepresentation of HPV/p16+ patients resulted in better than expected outcomes. © 2014 Wiley Periodicals, Inc. Head Neck, 2014 (Source: Head and Neck)

Mozambique: Health Ministry Confident on HPV Vaccination Target
Tue, 28 Oct 2014 05:18:56 +0100 | AllAfrica News: Health and Medicine
[AIM]Maputo -The Mozambican Health Ministry is confident that it will reach the target for the third and final dose of vaccination against HPV, the human papilloma virus, which causes cervical cancer. (Source: AllAfrica News: Health and Medicine)

HPV in head and neck cancers [Medical Sciences]
Tue, 28 Oct 2014 00:00:00 +0100 | Proceedings of the National Academy of Sciences
Previous studies have established that a subset of head and neck tumors contains human papillomavirus (HPV) sequences and that HPV-driven head and neck cancers display distinct biological and clinical features. HPV is known to drive cancer by the actions of the E6 and E7 oncoproteins, but the molecular architecture of... (Source: Proceedings of the National Academy of Sciences)